Tássia Joi Martins1,2, Laisa Bonafim Negri3,4,5, Laena Pernomian3,6, Kelson do Carmo Freitas Faial7, Congcong Xue2, Regina N Akhimie2, Michael R Hamblin8, Claudia Turro2, Roberto S da Silva1,3,4,5. 1. Department of Chemistry, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto University of São Paulo, Ribeirão Preto, Brazil. 2. Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, United States. 3. Department of Physics and Chemistry, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. 4. Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, United States. 5. Department of Dermatology, Harvard Medical School, Boston, MA, United States. 6. Department of Pharmacology of the School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. 7. Environmental Section, Evandro Chagas Institute (SAMAM/IEC), Ananindeua, Brazil. 8. Laser Research Center, Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa.
Abstract
This work presents a new procedure to synthesize ruthenium-phthalocyanine complexes and uses diverse spectroscopic techniques to characterize trans-[RuCl(Pc)DMSO] (I) (Pc = phthalocyanine) and trans-[Ru(Pc)(4-ampy)2] (II) (4-ampy = 4-aminopyridine). The triplet excited-state lifetimes of (I) measured by nanosecond transient absorption showed that two processes occurred, one around 15 ns and the other around 3.8 μs. Axial ligands seemed to affect the singlet oxygen quantum yield. Yields of 0.62 and 0.14 were achieved for (I) and (II), respectively. The lower value obtained for (II) probably resulted from secondary reactions of singlet oxygen in the presence of the ruthenium complex. We also investigate how axial ligands in the ruthenium-phthalocyanine complexes affect their photo-bioactivity in B16F10 murine melanoma cells. In the case of (I) at 1 μmol/L, photosensitization with 5.95 J/cm2 provided B16F10 cell viability of 6%, showing that (I) was more active than (II) at the same concentration. Furthermore, (II) was detected intracellularly in B16F10 cell extracts. The behavior of the evaluated ruthenium-phthalocyanine complexes point to the potential use of (I) as a metal-based drug in clinical therapy. Changes in axial ligands can modulate the photosensitizer activity of the ruthenium phthalocyanine complexes.
This work presents a new procedure to synthesize ruthenium-phthalocyanine complexes and uses diverse spen class="Gene">ctroscopic techniques to characterize trans-[RuCl(Pc)DMSO] (I) (Pc = phthalocyanine) and trans-[Ru(Pc)(4-ampy)2] (II) (4-ampy = 4-aminopyridine). The triplet excited-state lifetimes of (I) measured by nanosecond transient absorption showed that two processes occurred, one around 15 ns and the other around 3.8 μs. Axial ligands seemed to affect the singlet oxygen quantum yield. Yields of 0.62 and 0.14 were achieved for (I) and (II), respectively. The lower value obtained for (II) probably resulted from secondary reactions of singlet oxygen in the presence of the ruthenium complex. We also investigate how axial ligands in the ruthenium-phthalocyanine complexes affect their photo-bioactivity in B16F10murinemelanoma cells. In the case of (I) at 1 μmol/L, photosensitization with 5.95 J/cm2 provided B16F10 cell viability of 6%, showing that (I) was more active than (II) at the same concentration. Furthermore, (II) was detected intracellularly in B16F10 cell extracts. The behavior of the evaluated ruthenium-phthalocyanine complexes point to the potential use of (I) as a metal-based drug in clinical therapy. Changes in axial ligands can modulate the photosensitizer activity of the ruthenium phthalocyanine complexes.
Authors: Joana Teles Ferreira; João Pina; Carlos Alberto Fontes Ribeiro; Rosa Fernandes; João P C Tomé; M Salomé Rodríguez-Morgade; Tomás Torres Journal: J Mater Chem B Date: 2017-07-12 Impact factor: 6.331
Authors: Juan Zhang; Chengshi Jiang; João Paulo Figueiró Longo; Ricardo Bentes Azevedo; Hua Zhang; Luis Alexandre Muehlmann Journal: Acta Pharm Sin B Date: 2017-09-22 Impact factor: 11.413
Authors: Kelly A D F Castro; Juliana A Prandini; Juliana Cristina Biazzotto; João P C Tomé; Roberto S da Silva; Leandro M O Lourenço Journal: Front Chem Date: 2022-03-14 Impact factor: 5.221